Equities analysts predict that Antares Pharma Inc (NASDAQ:ATRS) will report earnings per share (EPS) of ($0.02) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.01). Antares Pharma reported earnings per share of ($0.01) during the same quarter last year, which indicates a negative year over year growth rate of 100%. The company is scheduled to announce its next earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Antares Pharma will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.10) to ($0.05). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. The company had revenue of $28.43 million during the quarter, compared to the consensus estimate of $21.66 million.
Shares of NASDAQ ATRS traded down $0.12 during midday trading on Thursday, hitting $3.12. 663,380 shares of the company’s stock were exchanged, compared to its average volume of 1,024,493. The company has a quick ratio of 2.87, a current ratio of 3.46 and a debt-to-equity ratio of 1.01. Antares Pharma has a 12 month low of $2.53 and a 12 month high of $3.96. The company’s 50 day moving average price is $3.21 and its 200 day moving average price is $3.10. The firm has a market capitalization of $508.75 million, a PE ratio of -78.00 and a beta of 0.95.
Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its stake in shares of Antares Pharma by 54,541.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 30,053 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 29,998 shares during the period. Searle & CO. bought a new stake in Antares Pharma in the 1st quarter valued at $61,000. Perkins Capital Management Inc. boosted its stake in Antares Pharma by 7.8% in the 1st quarter. Perkins Capital Management Inc. now owns 441,000 shares of the specialty pharmaceutical company’s stock valued at $1,336,000 after purchasing an additional 32,000 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Antares Pharma in the 1st quarter valued at $123,000. Finally, Enterprise Bank & Trust Co bought a new stake in Antares Pharma in the 1st quarter valued at $45,000. Institutional investors own 43.10% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.